Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00527033
Status:
COMPLETED
Last Update Posted:
2017-02-16
First Post:
2007-09-06
Brief Title:
A Study of YM178 in Patients With Symptomatic Overactive Bladder
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Double-blind Parallel-group Placebo-controlled Study in Patients With Symptomatic Overactive Bladder
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Examine which dose of YM178 is the best in terms of efficacy safety and tolerability compared to placebo
Detailed Description:
To investigate the dose-response relationship of YM178 in terms of efficacy safety and tolerability and also the superiority of YM178 over placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None